Association of Uremic Solutes With Cardiovascular Death in Diabetic Kidney Disease.

RATIONALE AND OBJECTIVE Cardiovascular disease (CVD) is a major cause of mortality among people with diabetic kidney disease (DKD). The pathophysiology is inadequately explained by traditional CVD risk factors. Three uremic solutes, trimethylamine-N-oxide (TMAO), asymmetric and symmetric dimethylarginine (ADMA, SDMA), have been linked to CVD in kidney failure with renal replacement therapy (KFRT), but data are limited in populations with diabetes and less severe kidney disease. STUDY DESIGN Observational cohort. SETTINGS AND PARTICIPANTS Random subcohort of 555 REGARDS Study participants with diabetes and eGFR <60 ml/min/1.73m2 at study entry. EXPOSURES ADMA, SDMA and TMAO were assayed by liquid chromatography-mass spectrometry in plasma and urine. OUTCOMES CV mortality (primary outcome), all-cause mortality and incident KFRT (secondary outcomes). ANALYTIC APPROACH Plasma and urine:plasma (U/P) ratios of ADMA, SDMA and TMAO were tested for association with outcomes. Adjusted Cox regression models were fitted and hazard ratios (HR) of outcomes presented per standard deviation, log2 increments and interquartile comparisons. RESULTS Mean baseline eGFR was 44 ml/min/1.73 m2. CV death, overall mortality and KFRT occurred in 120, 285 and 89 participants during mean 6.2 years follow-up. Higher plasma ADMA, and lower U/P ratios of ADMA, SDMA and TMAO were associated with CV mortality by interquartile (HR 1.9-3.9), log2 concentration comparisons (HR 1.4-2.1), and per standard deviation (HR 1.2). Higher plasma concentrations (HR 1.1-2.8) and lower U/P ratios (HR 1.3-2.3) of all three solutes were associated with all-cause mortality. Higher plasma SDMA was associated with incident KFRT (HR 1.2-3.0). LIMITATIONS Single cohort, restricted to diabetic patients with eGFR <60, potential residual confounding by GFR, no dietary information. CONCLUSIONS Higher plasma concentrations and lower U/P ratios of uremic solutes were independently associated with CV and all-cause mortality in DKD. Associations of U/P ratios with mortality suggest a connection between renal uremic solute clearance and CVD pathogenesis.

[1]  N. Powe,et al.  New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. , 2021, The New England journal of medicine.

[2]  S. Waikar,et al.  Urinary Biomarkers and Kidney Outcomes: Impact of Indexing Versus Adjusting for Urinary Creatinine , 2021, Kidney medicine.

[3]  B. Urquhart,et al.  Uremic Toxins in the Progression of Chronic Kidney Disease and Cardiovascular Disease: Mechanisms and Therapeutic Targets , 2021, Toxins.

[4]  R. Gansevoort,et al.  Use of the Urine-to-Plasma Urea Ratio to Predict ADPKD Progression. , 2021, Clinical journal of the American Society of Nephrology : CJASN.

[5]  M. Krempf,et al.  Elevation of Trimethylamine-N-Oxide in Chronic Kidney Disease: Contribution of Decreased Glomerular Filtration Rate , 2019, Toxins.

[6]  J. Rodriguez-Perez,et al.  Asymmetric (ADMA) and Symmetric (SDMA) Dimethylarginines in Chronic Kidney Disease: A Clinical Approach , 2019, International journal of molecular sciences.

[7]  Angela M. Malek,et al.  The association of age at menopause and all-cause and cause-specific mortality by race, postmenopausal hormone use, and smoking status , 2019, Preventive medicine reports.

[8]  T. Meyer,et al.  Uremic Toxin Clearance and Cardiovascular Toxicities , 2018, Toxins.

[9]  D. Fliser,et al.  Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease , 2018, Clinical Research in Cardiology.

[10]  K. Maeda,et al.  Involvement of Organic Cation Transporters in the Kinetics of Trimethylamine N-oxide. , 2017, Journal of pharmaceutical sciences.

[11]  W. Lieb,et al.  Asymmetric and symmetric dimethylarginine as risk markers for total mortality and cardiovascular outcomes: A systematic review and meta-analysis of prospective studies. , 2017, Atherosclerosis.

[12]  H. Parving,et al.  Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria , 2017, Cardiovascular Diabetology.

[13]  Wei Wu,et al.  Key Role for the Organic Anion Transporters, OAT1 and OAT3, in the in vivo Handling of Uremic Toxins and Solutes , 2017, Scientific Reports.

[14]  W. Lieb,et al.  Asymmetric and Symmetric Dimethylarginine as Risk Markers for Total Mortality and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Prospective Studies , 2016, PloS one.

[15]  Lena Osterhagen,et al.  Multiple Imputation For Nonresponse In Surveys , 2016 .

[16]  J. Spertus,et al.  Serum Trimethylamine-N-Oxide is Elevated in CKD and Correlates with Coronary Atherosclerosis Burden. , 2016, Journal of the American Society of Nephrology : JASN.

[17]  T. Meyer,et al.  Mechanism of Prominent Trimethylamine Oxide (TMAO) Accumulation in Hemodialysis Patients , 2015, PloS one.

[18]  K. Aasarød,et al.  Arginine, dimethylated arginine and homoarginine in relation to cardiovascular risk in patients with moderate chronic kidney disease. , 2015, Clinical biochemistry.

[19]  S. Hazen,et al.  Gut Microbiota-Dependent Trimethylamine N-Oxide (TMAO) Pathway Contributes to Both Development of Renal Insufficiency and Mortality Risk in Chronic Kidney Disease , 2015, Circulation research.

[20]  U. Patel,et al.  Cardiovascular complications of diabetic kidney disease. , 2014, Advances in chronic kidney disease.

[21]  D. Fliser,et al.  Dimethylarginines ADMA and SDMA: the real water-soluble small toxins? , 2014, Seminars in nephrology.

[22]  H. Völzke,et al.  Incidence of All-Cause and Cardiovascular Mortality Predicted by Symmetric Dimethylarginine in the Population-Based Study of Health in Pomerania , 2013, PloS one.

[23]  A. Khera,et al.  Symmetrical Dimethylarginine Predicts Mortality in the General Population: Observations From the Dallas Heart Study , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[24]  Kamyar Kalantar-Zadeh,et al.  Cardiovascular Burden Associated with Uremic Toxins in Patients with Chronic Kidney Disease , 2013, American Journal of Nephrology.

[25]  S. Hazen,et al.  Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. , 2013, The New England journal of medicine.

[26]  A. Akhmedov,et al.  Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. , 2013, Immunity.

[27]  Katrin Uhlig,et al.  Risk Prediction Models for Patients With Chronic Kidney Disease , 2013, Annals of Internal Medicine.

[28]  F. Bushman,et al.  Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis , 2013, Nature Medicine.

[29]  Harold I Feldman,et al.  Plasma metabolomic profiles in different stages of CKD. , 2013, Clinical journal of the American Society of Nephrology : CJASN.

[30]  John A. Cornell,et al.  Statistical Methods (7th ed.) , 2012 .

[31]  Brian J. Bennett,et al.  Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease , 2011, Nature.

[32]  R. Gerszten,et al.  Metabolite profiling identifies markers of uremia. , 2010, Journal of the American Society of Nephrology : JASN.

[33]  G. Beck,et al.  Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[34]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[35]  E. Benjamin,et al.  Plasma Asymmetric Dimethylarginine and Incidence of Cardiovascular Disease and Death in the Community , 2009, Circulation.

[36]  H. Mischak,et al.  Review on uraemic solutes II--variability in reported concentrations: causes and consequences. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[37]  J. Griffith,et al.  The Framingham predictive instrument in chronic kidney disease. , 2007, Journal of the American College of Cardiology.

[38]  R. Milne,et al.  Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[39]  G. Breithardt,et al.  Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. , 2006, Journal of the American Society of Nephrology : JASN.

[40]  G. Wolf,et al.  Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease – possible candidates for paradoxical epidemiology? , 2006, Amino Acids.

[41]  C. Moy,et al.  The Reasons for Geographic and Racial Differences in Stroke Study: Objectives and Design , 2005, Neuroepidemiology.

[42]  F. Kronenberg,et al.  Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. , 2005, Journal of the American Society of Nephrology : JASN.

[43]  Charles E McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[44]  P. Royston Multiple Imputation of Missing Values , 2004 .

[45]  Deeb N Salem,et al.  Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. , 2004, Journal of the American Society of Nephrology : JASN.

[46]  H. Prins,et al.  Handling of asymmetrical dimethylarginine and symmetrical dimethylarginine by the rat kidney under basal conditions and during endotoxaemia. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[47]  F. Schweitzer,et al.  Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in patients with chronic kidney diseases. , 2003, Clinica chimica acta; international journal of clinical chemistry.

[48]  D. Levy,et al.  Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.

[49]  R. Anderson,et al.  Urinary diagnostic indices in acute renal failure: a prospective study. , 1978, Annals of internal medicine.

[50]  Joshua Lederberg,et al.  Children's Hospital of Philadelphia. , 1975, The Australasian nurses journal.

[51]  E. N. Allott,et al.  UREMIA , 1963 .